Pre-Clinical Testing
More than 20 presentations from top academic and pharma institutions worldwide will demonstrate how innovations like Mission Bio’s Tapestri Platform are driving breakthroughs in hematology Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Dec. 5, 2024 – Mission Bio, a leader in single-cell multiomics solutions for precision medicine, today announced the full list of…
Read More
Data published in peer-reviewed npj Drug Discovery, a Nature portfolio journal Excerpt from the Press Release: BURLINGAME, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of preclinical data highlighting the potential of soquelitinib, the Company’s lead ITK inhibitor program, as a novel approach to…
Read More
First and only AKT inhibitor combination to demonstrate benefit in this specific subtype of prostate cancer Excerpt from the Press Release: WILMINGTON, Del.–(BUSINESS WIRE)–Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca’s TRUQAP® (capivasertib)in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically significant and clinically meaningful improvement in the…
Read More
Data presented at the AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and Macroenvironment in Cancer Results bolster Company’s rationale for incorporating DNase I as an adjunctive treatment to improve therapeutic responses in patients undergoing CAR T cell therapy Excerpt from the Press Release: FRAMINGHAM, MA / ACCESSWIRE / November 21,…
Read More
Peripherally-restricted nimacimab achieves significant dose-dependent weight loss, fat mass reduction, lean mass preservation, and glycemic control in diet-induced obesity model Preliminary data shows that nimacimab achieves desired metabolic outcomes without central inhibition and its risk of neuropsychiatric adverse events Excerpt from the Press Release: SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) — Skye Bioscience, Inc.…
Read More
-Transenteric delivery of incretin triagonist GLP-1, GIP, glucagon receptors mimicking the RaniPill route of administration elicits rapid weight loss and bioavailability comparable to subcutaneous injection – – New pharmacokinetic data provides further evidence of the RaniPill platform’s potential to enable oral delivery of multiple obesity treatments – – Phase 1 study for RT-114, an oral…
Read More
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical-stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced encouraging preclinical data on PIPE-307,a potentially first-in-class M1…
Read More
The deal is the third recent buyout of a radiopharmaceutical developer in recent months, following similar deals from Eli Lilly and Bristol Myers Squibb. Excerpt from the Press Release: AstraZeneca is the latest large pharmaceutical company to make a sizable bet on radiopharmaceutical drugs for cancer, agreeing on Tuesday to acquire longtime biotechnology partner Fusion…
Read More
Preclinical Studies Show DA-1726 Elicits Superior Weight Loss Compared to Semaglutide (Wegovy™) and Similar Weight Loss Compared to Tirzepatide (Mounjaro™), While Consuming More Food Initiation of Phase 1 Clinical Trial Expected to Occur in the First Half of 2024 Excerpt from the Press Release: CAMBRIDGE, Mass., Feb. 1, 2024 /PRNewswire/ — NeuroBo Pharmaceuticals, Inc. (Nasdaq:…
Read More
Maze Therapeutics Announces Initiation of Dosing in Phase 1 Trial Evaluating MZE829, a Novel Oral APOL1 Inhibitor, as a Potential Treatment for APOL1 Kidney Disease Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced the initiation of dosing in the company’s Phase…
Read More